COVID-19

The FDA is not required to follow the committee's advice, but it is expected to do so.

Pharmacists can prepare themselves to address patients’ questions and concerns about the COVID-19 vaccines.

Here’s a roundup of the latest coronavirus-related news.

Pharmacists may be among the first of the prioritized groups to be offered the COVID-19 vaccine once it receives FDA authorization.

CVS Health will pilot the administration of a limited supply of the monoclonal antibody therapy bamlanivimab to eligible patients at home or in long-term care facilities.

A survey conducted by the American Pharmacists Association asked pharmacists if they were ready to receive and administer COVID-19 vaccines.

The first doses of the mRNA COVID-19 vaccine will be delivered in the UK in the next few days, Pfizer announced.

Moderna reported an efficacy rate of 94.1% for its COVID-19 vaccine based on the primary efficacy analysis.

A recent study showed “alarming” rates of reported loneliness, anxiety, depression, and substance use in young adults during COVID-19.

Here’s a roundup of this week’s coronavirus-related news.

A study to be presented at the annual meeting of the Radiological Society of North America reported that COVID-19 patients with diabetes and hypertension may have a higher risk for neurologic complications.

As coronavirus disease 2019 (COVID-19) cases rise across the country, members of the MJH Life Sciences COVID-19 Coalition shared their perspectives on pandemic containment efforts.

Infectious Disease Society of America offered a look at the current treatment options for COVID-19 and stressed the need to maintain precautions to keep people safe.

One vaccine dosing regimen for AZD1222 showed 90% efficacy, according to investigators at the University of Oxford.

Here's the roundup of this week's coronavirus-related news.

Results from the NIAID-sponsored ACTT-2 trial showed that COVID-19 patients treated with baricitinib in combination with remdesivir experienced better recovery times and clinical status.

Pfizer and BioNTech expect to produce up to 50 million doses globally in 2020 and up to 1.3 billion doses by the end of 2021.

Officials with Operation Warp Speed said distribution of a COVID-19 vaccine will begin within 24 hours after FDA authorization.

Pfizer and BioNTech today announced that their COVID-19 vaccine candidate showed a 95% efficacy rate in the final analysis of its phase 3 study.

Moderna announced today that its messenger RNA vaccine candidate for COVID-19 met the primary endpoint of efficacy, according to the study’s first interim analysis.

Here’s a roundup of the latest coronavirus-related news.

As part of a new partnership with HHS, the nation’s largest pharmacy chains—as well as independents and regional chains—will be administering free coronavirus disease 2019 (COVID-19) vaccines when they are available.

The FDA has granted Fast Track Designation for NVX-CoV2373, a vaccine candidate for COVID-19.

The FDA has authorized Lilly’s investigational neutralizing antibody for COVID-19 treatment in the outpatient setting.

Interim analysis results from a phase 3 clinical trial reported a vaccine efficacy rate above 90% for BNT162b2. The trial is ongoing until it meets its threshold for confirmed COVID-19 cases.

Here's the coronavirus-related news from this week.

MJH Life Sciences™ COVID-19 Coalition will be hosting its next live webinar event “Thinking Long-Term: COVID-19’s Clinical Consequences and Mental Health Effects."

Members of the MJH COVID-19 Coalition were surveyed about strategies for pandemic containment.

The UK study examined the cross-sectional association between vitamins A, E, C, and D and respiratory complaints.

Here’s a preview of the featured content to watch for this week on Drug Topics®.